Class I
Ongoing
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
Why: Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
- Company
- Fresenius Kabi USA, LLC
Lake Zurich, IL, United States - Reported
- Sep 2, 2026
- Recall started
- Aug 10, 2026
- Where sold
- Nationwide in the USA
- Amount
- 4,643 20mL-vials
- Full product description
- Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
- Lots / codes affected
- Lot: 16UI07, Exp 08/31/2028
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.